PROM1 and liver cancer: In the current work, we endeavor to improve the targeting of liver cancer stem cells of doxorubicin (DOX) via conjugating DOX to an aptamer against CD133, a confirmed liver cancer stem cell marker with elevated expression in liver cancer cells [4].